PPIB and muscular dystrophy: Our findings also raise the possibility that this could turn out to be a side effect of non-immunosuppressive cyclophilin binding drugs, which are currently being tested clinically for anti-viral properties [42] and proposed as a new treatment for muscular dystrophy in order to inhibit cyclophilin D [43].